Continuous lenalidomide treatment for newly diagnosed multiple myeloma

The New England Journal of Medicine
Antonio PalumboMM-015 Investigators

Abstract

Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P<0.001) or MP (13 months; hazard ratio, 0.40; P<0.001). Response rates were superior with MPR-R and MPR (77% and 68%, respectively, vs. 50% with MP; P<0.001 and P=0.002, respectively, for the comparison with MP). The progression-free survival benefit associated with MPR-R was noted in patients 65 to 75 years o...Continue Reading

References

Oct 4, 1979·The New England Journal of Medicine·D E BergsagelA B Miller
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboUNKNOWN GIMEMA--Italian Multiple Myeloma Network
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cyrille HulinPhilippe Moreau
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria-Victoria MateosJesús F San Miguel
May 8, 2010·Blood·Anders WaageUNKNOWN Nordic Myeloma Study Group
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson

❮ Previous
Next ❯

Citations

Mar 12, 2013·International Journal of Hematology·Reiko WatanabeMasahiro Kizaki
Oct 1, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Isabelle Vande Broek, Peter Jacobs
Feb 15, 2014·The Lancet Oncology·Guy Pratt
Jun 6, 2012·Nature Reviews. Clinical Oncology·S Vincent Rajkumar
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
Aug 2, 2013·The New England Journal of Medicine·María-Victoria MateosJesús-F San Miguel
Jun 12, 2013·Thyroid : Official Journal of the American Thyroid Association·Francesco TorinoSalvatore Maria Corsello
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J L Harousseau
Aug 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Working Group
Jan 8, 2013·Japanese Journal of Clinical Oncology·Kenshi Suzuki
Mar 21, 2013·Anti-cancer Drugs·Yandun ZouJinming Yu
Dec 10, 2013·Hematology·María-Victoria Mateos, Jesús F San Miguel
Dec 6, 2012·Experimental Hematology & Oncology·Tahir LatifSaad Z Usmani
Sep 8, 2012·Cancer Management and Research·Niels Wcj van de DonkKenneth C Anderson
May 2, 2013·Haematologica·Antonio Palumbo, Federica Cavallo
Feb 7, 2013·Oman Medical Journal·Khalil Al-Farsi
Jul 6, 2014·Haematologica·Sonja ZweegmanPieter Sonneveld
Nov 29, 2013·International Journal of Hematologic Oncology·Jagoda K Jasielec, Andrzej J Jakubowiak
Jul 11, 2013·Future Oncology·Peter A Forsberg, Tomer M Mark
Nov 19, 2013·Journal of Comparative Effectiveness Research·Boris FreidlinEdward L Korn
Nov 8, 2012·Future Oncology·Alessandra LaroccaAntonio Palumbo
May 23, 2014·Der Radiologe·E K Mai, H Goldschmidt
Apr 5, 2014·Journal of the National Cancer Institute·Sascha A TuchmanJerome W Yates
Sep 4, 2014·The New England Journal of Medicine·Antonio PalumboMichele Cavo
Sep 13, 2014·Hematology/oncology Clinics of North America·Philippe MoreauThierry Facon
Sep 13, 2014·Hematology/oncology Clinics of North America·Heather Landau, Sergio Giralt
Sep 13, 2014·Hematology/oncology Clinics of North America·Philip L McCarthy, Antonio Palumbo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.